Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 4, 2013, Pages 402-405

  Jones, Ronald N ^a   Wilson, Michael L ^b   Weinstein, Melvin P ^c   Stilwell, Matthew G ^a   Mendes, Rodrigo E ^a  

^a JMI LABORATORIES   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

CLSI; EUCAST; Minocycline; Tetracycline

Indexed keywords

METICILLIN; MINOCYCLINE; TETRACYCLINE;

ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG POTENCY; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TETRACYCLINE;

EID: 84875277193     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.01.022     Document Type: Article

References (16)

1. Aminov R.I., Garrigues-Jeanjean N., Mackie R.I. Molecular ecology of tetracycline resistance: development and validation of primers for detection of tetracycline resistance genes encoding ribosomal protection proteins. Appl Environ Microbiol 2001, 67:22-32.
2. Barry A.L. The antimicrobic susceptibility test: principles and practices 1976, Lea & Fegiber, Philadelphia.
3. Bouchillon S.K., Hoban D.J., Johnson B.M., Johnson J.L., Hsiung A., Dowzicky M.J. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005, 52:173-179.
4. Bryskier A. Antimicrobial agents: antibacterials and antifungals 2005, ASM Press, Washington, D.C.
5. Burgess D.S., Frei C.R., Lewis J.S.I., Fiebelkorn K.R., Jorgensen J.H. The contribution of pharmacokinetic-pharmacodynamic modeling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clin Microbiol Infect 2006, 13:33-39.
6. Christianson J., Andes D., Craig W.A. Magnitude of the 24-h AUC/MIC required for efficacy of doxycycline against Streptococcus pneumoniae in a murine thigh-infection model. 41st ICAAC, December 16-19, 2001. Abst. A-1104. Chicago, IL, USA 2001.
7. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition, M07-A9 2012, CLSI, Wayne, PA.
8. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, CLSI, Wayne, PA.
9. Dowzicky M.J., Park C.H. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008, 30:2040-2050.
10. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. Available at . Accessed January 2, 2013. http://www.eucast.org/clinical_breakpoints/.
11. Grohs P., Trieu-Cuot P., Podglajen I., Grondin S., Firon A., Poyart C., et al. Molecular basis for different levels of tet(M) expression in Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother 2012, 56:5040-5045.
12. Iyer V., Bhavnani S.M., Ambrose P.A. Pharmacokinetics-pharmacodynamics: a primer for the clinical microbiologist. Clin Microbiol Newsl 2011, 33:127-131.
13. Jones R.N. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003, 24:121-134.
14. LaPlante K.L., Leonard S.N., Andes D.R., Craig W.A., Rybak M.J. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 2008, 52:2156-2162.
15. Minocin® Product Package Insert, 2010. Triax Pharmaceuticals. Available at . Accessed January 2013. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=32568.
16. Waites K.B., Duffy L.B., Dowzicky M.J. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006, 50:3479-3484.